Sexually Transmitted Infections – Rapid Testing at the Point of Care

Home - Industry Articles & White Papers

Sexually Transmitted Infections – Rapid Testing at the Point of Care

Urgency, Challenges and Advances in STI Testing

Sexually transmitted infections (STIs) are a major global health issue, with over 30 pathogens causing an estimated one million infections daily, a number that is rising. Surveillance programs in countries like the United States and Canada have reported an increase in STIs such as syphilis, gonorrhoea, and chlamydia. STIs can have serious consequences for sexual health, including infertility and chronic pelvic pain, particularly affecting women. The World Health Organization (WHO) has recognised the urgency of addressing this problem and has recommended measures to end the STI healthcare issue by 2030. Integrated testing, including multiplex and point-of-care testing, is considered essential. However, implementation of these recommendations at regional and national levels is lacking. Rapid point-of-care PCR tests that can detect multiple pathogens simultaneously would greatly improve STI diagnosis and containment. Currently, Randox, in collaboration with Bosch offers two STI test panels on the Vivalytic POC system: Vivalytic STI and Vivalytic MG, MH, UP/UU panels, capable of detecting multiple pathogens in a single test run, with results available within hours.

The Global Burden

  • The WHO estimates 374 million new infections of chlamydia, gonorrhoea, syphilis, and trichomoniasis annually.
  • Chlamydia is the most frequently reported STI in Europe, followed by gonorrhoea and syphilis.
  • Countries with comprehensive STI screening programs, like Denmark, have higher prevalence rates than the European average.
  • The UK has a comprehensive screening program for chlamydia targeting 15-24-year-olds, with cases accounting for 60% of total cases in the European Region.
  • The actual infection rate in countries without systematic screening is likely higher than official figures suggest.
  • Reported cases of gonorrhoea and syphilis in the European Region have increased, particularly among certain age groups and higher numbers in men than women.
Global Burden

Gaps in Current STI Testing Strategies

The European Centre for Disease Prevention (ECDC) acknowledges the growing concern of STIs in Europe and emphasises the importance of testing in their recent report. While various European countries have screening programs for chlamydia, testing options for other STI pathogens are usually limited. The lack of accessible testing, combined with the prevalence of asymptomatic infections, increases the risk of STI transmission and hampers containment efforts. Prevention campaigns and low-threshold testing opportunities are crucial to address the spread of STIs. The UK’s chlamydia screening program, implemented in 2008, demonstrated the benefits of community-based testing services and led to a significant increase in diagnosed cases, reducing the number of unreported cases.

Infections

Infections and Co-Infections

  • Co-infections, where multiple sexually transmitted pathogens are present simultaneously, are common but often go undetected due to limited testing.
  • Symptoms of co-infections can be difficult to differentiate since different pathogens can cause similar or overlapping symptoms.
  • However, most STIs, even in high-risk groups, are caused by a single sexually transmitted pathogen.
  • In cases where co-infections need to be detected, a rapid and comprehensive differential diagnosis of sexually transmitted pathogens is crucial for initiating appropriate therapy promptly.

The Importance of Rapid Results at the Point of Care

  • Rapid detection and treatment of STIs are crucial to prevent further spread.
  • Traditional STI diagnostics in specialized laboratories can result in delays of several days or up to 1-2 weeks until test results are available to the physician.
  • Delays occur due to transportation of samples, laboratory workflow, result transfer, and scheduling additional appointments.
  • The delay in treatment initiation can lead to decreased patient compliance and missed appointments.

The Vivalytic STI test provides results directly at the point of care (POC) in less than two and a half hours. It eliminates the need for sample transportation to a central laboratory. In addition, patients can receive their test results on the same day of the visit, allowing for immediate initiation of appropriate treatment.

2017-08-02-BHCS_Vivalytic-Anwendung-0616-CMYK-Edited

In a Nutshell

Sexually transmitted infections (STIs) spread due to various factors. Many STIs do not show symptoms, resulting in numerous unreported and untreated cases that can have fatal consequences depending on the specific pathogen. Increasing awareness and implementing a decentralised low-threshold testing strategy can significantly reduce infections, particularly among high-risk groups. Speed and comprehensive testing of relevant pathogens are crucial for targeted therapy and containing STIs. Rapid PCR tests used at the point of care (POC) are emerging as important technologies due to their advantages. Patients receive same-day results and immediate treatment, providing clarity in just one visit. Clinicians can provide up-to-date diagnoses and treatments, even in decentralised or hospital settings, benefiting high-risk patients with limited access to healthcare.

Vivalytic

The Bosch Vivalytic, is an advanced and automated platform for molecular diagnostics that utilises PCR to detect pathogens. It offers applications for various medical disciplines and requires only a few steps from sample collection to obtaining results. The patient sample is processed automatically within the Vivalytic analyser, and the test result is displayed on its integrated screen. The time it takes to get results depends on the specific Vivalytic application. For the STI Panel, which simultaneously detects 10 common sexually transmitted pathogens, the time to result is 2.5 hours. On the other hand, the Vivalytic MG, MH, UP/UU panel, used to detect mycoplasmas and/or ureaplasmas, provides results in approximately one hour.

By conducting fully automated analyses at the point of care, Vivalytic saves valuable time for hospitals, labs, genitourinary clinics and doctor’s offices during their routine processes.

STI PanelMG, MH, UP, UU Panel
Chlamydia trachomatisMycoplasma genitalium
Neisseria gonorrhoeaeMycoplasma hominis
Trichomonas vaginalisUreaplasma parvum/Ureaplasma
Mycoplasma genitalium
Treponema pallidum
Mycoplasma hominis
Ureaplasma urealyticum
Haemophilus ducreyi
Herpes simplex virus I
Herpes simplex virus II

At a Glance

  • The Vivalytic system allows fully automated sample analysis with minimal manual steps.
  • It eliminates the need for expensive and complex laboratory equipment.
  • Vivalytic supports both single and multiplex tests.
  • The Vivalytic does not require peripheral equipment such as a laptop, keyboard, barcode scanner, or charging station.
  • The cartridge used in the system ensures hygienic and safe operation as a closed system.
  • Cartridges can be stored and used at room temperature.
  • Vivasuite, a cloud-based solution, facilitates convenient device management.
  • The Vivalytic can be seamlessly integrated into existing IT structures using HL7, Ethernet, USB, or WLAN.
Vivalytic Reflection

For more information please contact us at: marketing@randox.com


Rapid PCR MRSA/SA testing now available on Vivalytic

https://www.linkedin.com/company/107191

Rapid PCR MRSA/SA testing now available on Vivalytic

Providing a quick diagnosis of methicillin resistant at the point of the care, the latest addition to the Vivalytic portfolio of tests, not only provides rapid RT-PCR results in 53 minutes but differentiates whether the bacterial strain is methicillin-resistant (MRSA) or methicillin-sensitive (MSAA) which promotes targeted therapy.

MRSA is a major multi-resistant nosocomial pathogen worldwide with the WHO estimating that the mortality rate of patient infection rates is around 50% higher compared with patients who have been infected by non-resistant Staphylococcus aureus strains.1 Moreover, the extensive period of hospitalisation, morbidity, and the associated medical costs increase significantly with an MRSA infection.2

Introducing MRSA to the vivalytic portfolio can provide high quality answers, anywhere and anytime improving patient pathways and the need for care. Significantly, introducing rapid MRSA screening at both ward level, emergency settings and before hospital elective surgery procedures allow for an effective response to identifying whether the bacteria strain is methicillin-sensitive (MSSA) or -resistant.

Making a point to care, the rapid essence and speed of Vivalytic not only showcase technology but the ability to contribute to current health risks by preventing contamination, breaking the chain of infection, and again fighting the silent pandemic of antimicrobial resistance (AMR) & superbugs.

The treatment on the front line today looks at increasing empirical antibiotic prescribing and increasing drug-resistant outbreaks. AMR is growing rapidly, with superbugs threatening the ability to treat common infectious diseases appropriately. The COVID-19 pandemic has elevated concerns over AMR and antibiotic-associated adverse events, with surges in antibiotic prescribing, hospitalisations, and drug-resistant bacterial transmissions.

Speed is key here – since the result of diagnostics with culture sampling, which is the current traditional method for MRSA testing is only available after one to three days, this PCR test for the point of care is ideal as an additional tool when speed is of the essence.

 

Few points to note about the current Vivalytic panel for MRSA/SA detection:

  • By using one single cartridge, the Vivalytic MRSA/SA test detects and differentiates between MRSA and MSSA DNA to aid in the diagnosis of MRSA infection in a speedy manner so that appropriate antibiotic treatment can be applied, and complications prevented.
  • Detection Method: Real-Time PCR
  • Result Time: 53 minutes
  • Sample Volume: 600 μl
  • Sample Type: Nasal- or oropharyngeal swab sample

 

DETECTABLE DNA PATHOGENS:SPECIFIC GENE TARGETS:
Methicillin-resistant Staphylococcus aureus (MRSA)SCCmec/orfX junction
Methicillin-sensitive Staphylococcus aureus (MSSA) mecA/ mecC, SA422

Making this happen, The MRSA/SA rapid test on Vivalytic by Bosch, a point of care platform brought to the market by Randox Laboratories. The Vivalytic system is a fully automated, cartridge-based platform capable of both Hi-Plex and Lo-Plex infectious disease testing. Each easy-to-use cartridge contains all necessary reagents, is fully-sealed to minimise risk and can be conveniently stored at room temperature.

The Vivalytic consolidates the full molecular workflow into a small benchtop platform, capable of extraction, PCR amplification and detection.  It follows an easy 4 step process from sample entry to results and with the gold standard PCR testing. With most up to date technology, the Vivalytic has wireless connectivity, with no peripherals required, making a unique space saving and hygienic solution. Handling and utilisation are simple and medical professionals require only minimal training.

For more information on the Vivalytic, why not visit our webpage- https://www.randox.com/vivalytic-molecular-point-of-care/

For more information on our new MRSA test, please contact market@randox.com

 

ABOUT RANDOX

NEWS

VACANCIES

OUR PEOPLE


Identification and Differentiation of Viral and Bacterial Respiratory Infection to Guide Antibiotic Stewardship

https://www.linkedin.com/company/107191

Identification and Differentiation of Viral and Bacterial Respiratory Infection to Guide Antibiotic Stewardship

 

The development of point-of-care testing is critical in the identification and differentiation between bacterial and viral respiratory infections. Defining the indications of infection to improve antibiotic stewardship, ensures that patients are protected from unnecessary antibiotic use and antibiotic resistance. It has been shown that particular protein biomarkers, such as myxovirus resistance protein (MxA) and C-reactive protein (CRP), differentiate infections between bacterial and viral. Using point-of-care platforms, such as Randox’s VeraSTAT, for detection of these protein biomarkers may provide more rapid and cost-effective discriminating tools.

The treatment of bacterial and viral infections can differ significantly, however people are often treated with empirical antibiotics due to a lack of paid and accurate testing. Although early intervention of infection is urgent, current diagnostic methods are either time intensive or inaccurate. The challenges clinicians are faced with in the differentiation of viral or bacterial respiratory infection can lead to delayed diagnosis, misappropriation of antibiotics and increased healthcare costs.

MxA protein has the potential to greatly enhance the rapid detection of viral respiratory infections as it increases significantly when there is actuate viral infection. CRP is the dominant acute phase protein often used to guide treatment of a bacterial infection or inflammation associated with tissue injury, inflammatory disorders, and associated diseases.

CRP & MxA together, allow clinicians to make appropriate decisions in supporting antimicrobial stewardship and guide the appropriate use of antibiotics, saving time performing unnecessary tests, providing unnecessary treatment which missing the opportunity to provide the right treatment in a timely manner.

The Randox VeraSTAT is a simple, accurate, portable point of care device which delivers rapid results via the use of patented cathodic electrochemiluminescence technology (C-ECL). Designed with the aim of offering users the next generation of rapid diagnosis, the VeraSTAT eliminates the requirement to send samples to a laboratory and instead returns results in as little as 6 minutes.

 

  • Eliminates delays in sending samples to the lab and facilitate immediate decision making at the point of care.
  • Lightweight, portable and convenient, the Randox VeraSTAT can be used in a variety of locations to deliver results as required, such as a GP surgery or Emergency Department.
  • Intuitive user interface guides the operator through the entire testing process.
  • All necessary reagents are conveniently included in each single use, sealed cassette with no preparation required. All necessary consumables are supplied with the kit.
  • The Randox VeraSTAT allows for results to be exported via Bluetooth connectivity.
  • Flexible test menu comprising of a range of immunoassay, protein, inflammatory, diabetes & infectious disease markers.

 

Novel testing approaches identifying the type of infection at the point of care are essential in accurately guiding appropriate antibiotic treatment. Although these tests can’t determine what type of viral or bacterial infection a patient has, it will determine whether the infection is viral or bacterial, further testing is then carried out to determine what type of pathogen the patient has via PCR – the gold standard. The ability to distinguish between viral and bacterial infections is the most effective guide for clinical decision making and is an innovative tool for antibiotic stewardship.

 

References

1 – Fleming-Dutra K.E., Hersh A.L., Shapiro D.J. Prevalence of inappropriate antibiotic prescriptions among US ambulatory care visits, 2010–2011. JAMA. 2016;315:1864–1873. doi: 10.1001/jama.2016.4151.

2 – Cals JW, Hopstaken RM, Butler CC, Hood K, Severens JL, Dinant GJ. Improving management of patients with acute cough by C-reactive protein point of care testing and communication training (IMPAC3T): study protocol of a cluster randomised controlled trial. BMC Fam Pract. 2007;8:15.

3- New report calls for urgent action to avert antimicrobial resistance crisis [Internet]. World Health Organization. World Health Organization; 2019

4 – Hutchings MI, Truman AW, Wilkinson B. Antibiotics: past, present and future. Curr Opin Microbiol. (2019) 51:72–80. doi: 10.1016/j.mib.2019.10.008

 

For more enquiries please contact the Marketing team: market@randox.com

ABOUT RANDOX

NEWS

VACANCIES

OUR PEOPLE


Celebrating World Hepatitis Day 2022!

Hepatitis is a condition that affects the liver and can be caused by an infection with a virus. With five different types of Hepatitis from A to E, the most common types of viral Hepatitis are A, B and C. These three viruses affect millions of people worldwide, causing both short-term illnesses and long-term liver disease.

World Hepatitis Day highlights the need to accelerate the fight against viral hepatitis and the importance of testing and treatment for those in need. The “I can’t wait” campaign brought to us by World Hepatitis Alliance, amplifies the voices of those affected demanding immediate action and the end of the stigma and discrimination attached.

Currently there are 325 million people who live with hepatitis globally with more than 1.1 million lives lost to hepatitis B and hepatitis C.

It is important to note that the use of appropriate quality control measures is vital in ensuring the appropriate daily performance of the assay used in the laboratory independent of the technology.

Features & Benefits of Randox Molecular Blood Borne Virus (BBV) Controls

  • Traceable to International Standard (where available) or to Internal Reference Material
  • Liquid frozen for user convenience and ease of use
  • The panels are suitable for use with the majority of commercial and in-house molecular methods
  • Manufactured to ISO: 13485 quality standards

Download brochure here

In addition to this, we have our third party Infectious Disease (Serology) Controls which are designed to deliver a cost-effective, high-quality solution for the analysis of infectious disease. Our controls are compatible for use on wide range of immunoassay platforms.

Features and Benefits

  • Liquid ready to use – All samples are provided in a user-friendly, liquid ready-to-use format significantly reducing preparation time and the risk of pipetting errors.
  • Commutability- Manufactured from human plasma each control is designed to react to the test system in the same manner as the patient sample, helping to meet ISO 15189:2012 requirements.
  • True third-party controls – Designed to deliver an independent, unbiased assessment of performance with any instrument or method the Acusera range will help to meet ISO 15189:2012 requirements and eliminate the need for multiple instrument specific controls.
  • Reduced waste – With a working stability of 60 days art 2oc to 8oC waste and costs are kept to a minimum.
  • Consolidation – The availability of multi-marker controls will reduce the number of individual controls required ultimately reducing costs, time, and storage space.
  • Clinically relevant – Designed to challenge clinically relevant ranges our low reactive samples will ensure accurate and reliable instrument performance.
  • Acusera 24.7 – Our Acusera Infectious Disease (Serology) Controls are compatible for use with our interlaboratory data management software Acusera 24.7.

For more information about Third party Infectious Disease (Serology) Controls:

Visit our website: Serology Quality Controls

Or email: qualitycontrol@randox.com

Want to know more?

Contact us or Visit Acusera Serology

 

Contact Us
Visit the Acusera Serology page

Serology Control

Serology Brochure

Molecular IQC

Resource Hub


Randox Equine Awards NI 2022

https://www.linkedin.com/company/107191

Randox Congratulates Manor Equine Vets on winning Best Vet Practice Equine Award 2022

Randox would like to congratulate Manor Equine Vets on winning the Best Vet Practise award at the Randox Equine Awards NI 2022. The Best Veterinary Practise category also included a highly commended award for Oldstone Veterinary Clinic.

Quirine Tettelaar, owner of Manor Equine Vets said “I was very happy to win the award and it was a big surprise! I would like to thank all my lovely clients, friends, and family for their support over the last couple years since starting my business. Hard work and dedication really pays off. It was lovely to read all the comments people left to vote, that was the best part of the awards! I feel really appreciated.”

This event was hosted by Raymond Bready and held at the Titanic Hotel Belfast on Saturday 25th June 2022.

With over 400 guests attending, Randox highlighted the new VeraSTAT-V test which detects the earliest signs of inflammation in horse blood. This stable side test is easy to use and provides quantitative results in six minutes.

Randox testing allows for a healthy horse and healthy rider.

Manor Equine Vets, Quirine Tettelaar and Randox’s Connor Gallagher Celebrate Best Vet Award at The Randox Equine Awards NI 2022

For press enquiries please contact Ellen Watson in the Randox PR team:  randoxpr@randox.com

ABOUT RANDOX

NEWS

VACANCIES

OUR PEOPLE


Biomedical Science Day 2022

Th17 Biochip Array Banner

Biomedical Science Day 2022

Biomedical Science Day is taking place this year on Thursday 9th June 2022. This is an annual celebration to increase the awareness of Biomedical Science and to promote to the public the importance of it.

Biomedical scientists play a key role in diagnosis, quality development and assurance, treatment, research, and development in the modern medical sciences. To celebrate and give recognition we have interviewed one of our RCLS clinical deputy managers, Jayme Hamilton.

 

This is what Jayme has to say about his role in Biomedical Science:

 

 

1. What attracted you to pursue a career in biomedical science?

My degree was in Biological Sciences with Professional Studies. Through it, I was able to design my degree based in my own interests and curiosities, which drew me to exploring the molecular and chemical pathways that elicit biological pathways and also how biotechnology is opening up a future to personalised health and therapies. What I find interesting it how a complete complement of biomarkers needs to be assessed to offer a full illustration of what’s going on under the skin.

2. How many different labs have you worked in?

I have been fortunate to work within several Laboratories to some capacity early in my career. I had a very fulfilling placement within a Method Development and Validation lab at a pharmaceutical company, as well as completing a challenging honours project in population genetics in my final year of university.  Since joining Randox, I have had opportunities to work across several Clinical and Molecular Laboratories with talented colleagues from all sorts of backgrounds; within Liverpool and London in England, Holywood and Antrim in N. Ireland and Los Angeles in California.

 

3. Do you enjoy the practical or theoretical aspect of biomedical science?

Theoretical- I have a drive to learn and understand and thankfully in science that is a continuous journey, as new forms of diagnostics and analysis are born and our understanding can grow or even change.  With a good understanding of the science and a multidisciplinary team of talented individuals to collaborate with, it makes executing the practical work all the more rewarding.

 

4. What is your favourite part of your day in work?

The end of the day -but not why you might think. I have been trying to be more reflective and as the start of the day can be very busy and hands on, I have found it helpful to review my workload and responsibilities, as well as that of those I help lead, at the end of the day; to better look ahead to tomorrow and acknowledge the efforts of the team.

 

5. What’s in your lab coat pocket?

Pens, markers, and more pens. My favourite being my engineering pen, with a torch and stylus included.  Thankfully we push for a more paperless world, but a busy lab can need some quick notes to be made. I’m also a very visual person and find it easiest to communicate to colleagues with notes or even a quick sketch.

 

6. In your opinion, what are the most important aspects of laboratory work?

The results we release. Fundamentally the data we release it for the benefit to the individual they deprived from. By stringently monitoring our quality checks and adhering to the procedures and processes we implement, we can have confidence that the results we release have a high level qualitative and interpretive value.

 

7. In what ways does your work make a difference to people’s lives?

At a personal level, as a clinical deputy manager I aim to optimise and evolve the duties of the colleagues I work with to make their jobs easier and more fulfilling and by extension the functionality of the lab more efficient.

In doing so, I broadly think the work we are doing as a collective, is bringing personalised testing to the masses and in doing so, add to improving the public’s understanding of science, in such that they can begin to take their health into their own hands in a measurable and meaningful way.

 

8. What is your dream career within biomedical science?

Living the dream. So far in my career I have been able to learn and develop within a profession that aligns with my interests, whilst simultaneously contributing to expanding and exciting industry. Throughout which I have had the opportunity to collaborate with many fantastic, talented, intelligent and hardworking people, from an array of disciplines, during the growth of a impressive clinical testing service as well as a nationwide covid testing service.

 

 

 

 

Jayme is a fundamental member of Randox and plays an essential role in the team, as do all our employees. Without our valuable laboratory team working extremely hard behind the scenes the lifesaving work we do here at Randox would not be possible. We thank each one of you for your hard work every day.

To find out more about our Biomedical Science, contact us at market@randox.com

 

Want to know more?

Contact us or visit Biosciences

Contact Us
Visit our Biosciences Page

Lp(a) Calibrator

Lp(a) Control

Lipid EQA Scheme

Reagents Resource Hub


Celebrating Lp(a) Awareness Day 2022 today!

Randox are raising awareness for Lipoprotein(a), we want to drive awareness on tests that are available to you to decrease the risk of stroke, heart attack or other heart diseases.

Lp(a) is a risk factor for atherosclerosis and related diseases including CHD and stroke. It is increasingly recognised as the strongest known genetic risk factor for premature coronary artery disease. The biggest challenge that exists surrounding Lp(a) measurement is the heterogeneity of the apolipoprotein(a) isoforms, resulting in the underestimation or overestimation of Lp(a) concentrations.

Benefits of the Randox Lp(a) assay

WHO/IFCC reference material – The Randox Lp(a) assay is calibrated in nmol/l and traceable to the WHO/IFCC reference material (IFCC SRM 2B) and provides an acceptable bias compared with the Northwest Lipid Metabolism Diabetes Research Laboratory (NLMDRKL) gold standard method.

Dedicated calibrator & control available – Five point calibrator with accuracy-based assigned target values (in nmol/l) is available, accurately reflecting the heterogeneity of the apo(a) isoforms. Dedicated Lp(a) control is available offering a complete testing package.

Excellent correlation – A correlation coefficient of r=0.995 was displayed when the Randox method was compared against other commercially available methods.

Excellent precision – The Randox Lp(a) assay displayed a within run precision of <2.54%.

Liquid ready-to-use – The Randox Lp(a) assay is available in a liquid ready-to-use format for convenience and ease-of-use.

Applications available – Instrument-specific settings can be provided for a wide range of clinical chemistry analysers.

 

The biggest challenge that exists surrounding Lp(a) measurement is the heterogeneity of the apo(a) isoforms, resulting in the underestimation or overestimation of Lp(a) concentrations. In immunoassays, the variable numbers of repeated KIV-2 units in Lp(a) act as multiple epitopes. This is where standardisation across calibrators is vital. Unless the calibrants do have the same range of isoforms as test samples, those with higher numbers of the KIV-2 repeat, will represent with an overestimation in Lp(a) concentrations and those with smaller numbers of the KIV-2 repeat, will represent with an underestimation. The smaller isoforms are strongly associated with higher Lp(a) concentrations. Lack of standardisation of the calibrant would result in an underestimation of Lp(a) associated CVD risk. It is important to note that an Lp(a) immunoassay employing isoform insensitive antibodies does not exist.

 

DID YOU KNOW?

Lp(a) has been identified to be a key risk factor for cardiovascular complications in individuals with COVID-19!

It is well documented that pre-existing comorbidities such as diabetes and CVD are associated with greater severity and higher fatality rates in those with COVID-19.  Those with either baseline elevated Lp(a) or those whose Lp(a) levels increased following infection from COVID-19, or both, maybe at a significantly increased risk of developing thromboses. Elevated Lp(a) levels may cause acute destabilisation of pre-existing but quiescent, atherosclerotic plaques, which could induce an acute myocardial infarction or stroke.

Identifying any possible health conditions that would relate to early signs of stroke, heart attack or other heart diseases will allow you to make any decisions on an appropriate diet, lifestyle changes and early treatment to reduce your risk of further problems.

For more information about Lp(a):

Visit our website: Lipoprotein(a) [Lp(a)] | Reagents | Randox Laboratories

Or email: marketing@randox.com

 

Want to know more?

Contact us or visit Reagents

Contact Us
Visit the Reagents Page

Lp(a) Calibrator

Lp(a) Control

Lipid EQA Scheme

Reagents Resource Hub


SARS-CoV-2 Vascular & Multi-System Dysfunction Whitepaper

Randox Logo

30 June 2021

SARS-CoV-2 Vascular & Multi-System Dysfunction Whitepaper Download

COVID-19, the disease caused by SARS-CoV-2, is an infectious disease caused by a newly discovered coronavirus. While many of whom become infected by the disease will experience mild to moderate cold or flu-like symptoms, those with health complications – such as autoimmune diseases, asthma, heart disease and diabetes – are at risk of developing serious illness and adverse outcomes.

As of September 2021, over 228 million COVID-19 cases have been confirmed worldwide, with an estimated one in six patients experiencing complications which could be life threatening, with over £116 billion spent by the UK government alone on measures to combat the disease. This drastic spending has been mirrored across the globe, with the significant economic burden expected to be suffered for generations to come.

The whitepaper provides a brief overview of the COVID-19 pandemic, before discussing vascular abnormalities and associated complications brought on by the virus, such as multi-system disfunction, acute respiratory disease syndrome (ARDS) and hepatic, renal & cardiovascular function.

 

Want to know more about Randox?

Contact us or visit our homepage to view more.

Our COVID-19 Products and Services

HOME TEST

ANTIBODY TEST

TRAVEL CERTIFICATE

LABORATORY TOOLS


World Health Day 2021

Randox Logo

   

7th April 2021

Building a fairer, healthier world

World Health Day is a global health awareness day celebrated every year on 7th April, under the sponsorship of the World Health Organisation (WHO) who sees it as an opportunity to draw worldwide attention to a subject of major importance to global health. Each year is related to a particular theme and this year’s focus is “building a fairer, healthier world”.

In view of the ongoing global COVID-19 pandemic where restrictions remain in place across most parts of the world, this time has highlighted that some people are able to live healthier lives and have better access to health services than others. COVID-19 has hit all countries hard, but its impact has been harshest on those communities which were already vulnerable, who are more exposed to the disease, less likely to have access to quality health care services and more likely to experience adverse consequences as a result of measures implemented to contain the pandemic, placing additional stress on healthcare systems across the world.

The COVID-19 pandemic has disrupted and even halted particular health services with most countries (90%) reporting that many routine and elective services have been suspended, while critical care – such as cancer screening and treatment and HIV therapy has seen high-risk interruptions (WHO, 2020).

the enjoyment of the highest attainable standard of health is one of the fundamental rights of every human being without distinction of race, religion, political belief, economic or social condition.” (WHO, 2021).

Randox has adapted to the emergence of the COVID-19 pandemic by developing pioneering tests to diagnose COVID-19, offering a range of COVID-19 testing solutions using Randox’s patented Biochip Technology capable of conducting multiple tests simultaneously on a range of molecular testing platforms, with results available from the Vivalytic, Evidence Investigator and Randox Discovery.

With a game-changing global partnership formed between Randox Laboratories and Bosch Healthcare Solutions combining science and technology, successfully launching the Vivalytic – the all in one solution for molecular diagnostics, the Vivalytic has been designed against the challenges posed by climate change and to contribute towards sustainability. The Vivalytic cartridges are CO2 neutral – this means that emissions that are in our direct sphere of influence are neutralised – making a further contribution to climate protection.

Furthermore, Randox’s vision is to improve healthcare worldwide and to ensure physicians and the public have access to the latest advancements in clinical diagnostics to aid diagnosis, treatment, and management of patients. Randox offer a comprehensive biochip test menu to support and combat challenges facing global health on an everyday basis from testing for Chronic Lung Disease (CLD) to predicting Alzheimers Disease. View Randox’s full Biochip Technology Immunoassay test menu here.

Please contact marketing@randox.com for further information on any of the mentioned above.

Randox in the media

Latest News

FAQs


Approaching the Fundamental Impact of STIs Worldwide

Randox Logo

02 March 2021

The Global Economic Burden of STIs & The Impact of the COVID-19 Pandemic on Sexual Health Whitepaper Download 

Sexual Health encompasses; genito-urinary medicine, sexually transmitted infections (STIs), HIV, contraception, psychosexual medicine, abortion services, teenage pregnancy and sexual and reproductive health. It is delivered in various settings, providing care across specialised services as well as through primary and third sector organisations.

Sexual and reproductive health is a fundamental public health issue and is clearly recognised by the World Health Organisation (WHO). This whitepaper focuses on the profound impact of sexually transmitted infections (STIs) worldwide with WHO reporting that more than 1 million STIs are acquired every day (WHO, 2020).

The whitepaper discusses issues such as antimicrobial resistance, in particular gonorrhoea, and the challenges faced in a social and public concept due to the COVID-19 pandemic.

Want to know more about Randox?

Contact us or visit our homepage to view more.

Our COVID-19 Products and Services

HOME TEST

ANTIBODY TEST

TRAVEL CERTIFICATE

LABORATORY TOOLS